These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30142779)

  • 21. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
    Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
    Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
    [No Abstract]   [Full Text] [Related]  

  • 22. Improving clinical trials in higher-risk myelodysplastic syndromes.
    Sekeres MA
    Best Pract Res Clin Haematol; 2022 Dec; 35(4):101406. PubMed ID: 36517123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis.
    Du Y; Li C; Yan J
    Hematology; 2023 Dec; 28(1):2198098. PubMed ID: 37036307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
    Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
    Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
    Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
    Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
    Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
    J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
    Kirkizlar TA; Kirkizlar O; Demirci U; Umut A; Iflazoglu H; Umit EG; Demir AM
    Leuk Res; 2023 Apr; 127():107043. PubMed ID: 36801588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
    Trapè G; De Angelis G; Morucci M; Tarnani M; De Gregoris C; Di Veroli A; Panichi V; Topini G; Bassi L; Isidori R; Poscente M; Innocenti V; Cippitelli EE; Talucci R; Bertelli S; Crocicchia A; Lippi A; Pezzuti G; Fuschino M; Randi R; Mastini C; Ciambella S; Pessina G; Montanaro M; Latagliata R
    Eur J Haematol; 2023 Aug; 111(2):311-317. PubMed ID: 37231885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
    Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
    Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
    Taylor J; Mi X; Penson AV; Paffenholz SV; Alvarez K; Sigler A; Chung SS; Rampal RK; Park JH; Stein EM; Tallman MS; Sen F; Gönen M; Abdel-Wahab O; Klimek VM
    Lancet Haematol; 2020 Aug; 7(8):e566-e574. PubMed ID: 32735836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.